What are the key details and exam‑relevant points for the following topics: thrombolysis in acute ischemic stroke, antiplatelet therapy in elderly stroke patients, role of aspirin or clopidogrel in massive cerebral ischemia, intravenous immunoglobulin (IVIG) in Guillain‑Barré syndrome, deep brain stimulation (DBS) in Parkinson’s disease, finerenone in chronic kidney disease, desidustat in chronic kidney disease‑related anemia, intravenous iron supplementation for iron‑deficiency anemia, immunotherapy (checkpoint inhibitors and CAR‑T) in lymphoma, and portable or wearable dialysis devices for end‑stage renal disease?

Comprehensive Exam-Relevant Overview: Neurology, Nephrology, and Hematology-Oncology Topics

---

MODULE 3 – PAPER 1: NEUROLOGY / AGING / NUTRITION

1. Thrombolysis in Acute Ischemic Stroke

Administer IV alteplase (0.9 mg/kg, max 90 mg) within 3 hours of symptom onset for all eligible acute ischemic stroke patients 1, 2.

Time Windows & Evidence Strength:

• 0-3 hours: Class I, Level A recommendation—strongest evidence for benefit 1
• 3-4.5 hours: Grade 2C recommendation—weaker evidence but still beneficial in selected patients 1
• Beyond 4.5 hours: Not recommended (Grade 1B against) 1

Key Eligibility Criteria:

• Measurable neurological deficit on NIHSS
• No intracranial hemorrhage on CT/MRI
• Blood pressure <185/110 mmHg (must be controlled before treatment)
• No recent major surgery, GI/urinary bleeding, or arterial puncture at non-compressible site
• Platelet count >100,000/mm³, INR ≤1.7

Critical Pitfalls:

• Do NOT give aspirin within 24 hours of thrombolysis—increases hemorrhage risk without added benefit (Class III, Level A) 3
• Intraarterial thrombolysis may be considered within 6 hours for proximal occlusions in patients ineligible for IV therapy (Grade 2C) 1
• Mechanical thrombectomy currently has Grade 2C recommendation against routine use, though carefully selected patients may benefit 1

---

2. Antiplatelet Therapy in Elderly Stroke Patients

Start aspirin 160-325 mg within 24-48 hours of acute ischemic stroke onset in all patients, including elderly 1, 2, 4.

Evidence Base:

The combined data from two large trials (IST and CAST) involving >40,000 patients demonstrated modest but significant benefit: 13 fewer deaths or dependencies per 1000 treated (NNT=79) 4. Age is NOT a contraindication—the benefit-risk ratio remains favorable in elderly patients 5.

Long-term Secondary Prevention Options (all acceptable):

• Aspirin 75-100 mg daily (least expensive, baseline option)
• Clopidogrel 75 mg daily (preferred if aspirin-intolerant; Grade 2B over aspirin) 1
• Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily (Grade 2B over aspirin alone) 1

Special Considerations for Elderly:

• Higher bleeding risk with dual antiplatelet therapy—avoid routine aspirin + clopidogrel combination (Class III, Level A) 5, 1
• Clopidogrel monotherapy reasonable if aspirin allergy (Class IIa, Level B) 5
• If stroke occurs while on aspirin, switch to alternative agent rather than increasing aspirin dose 6

---

3. Role of Aspirin/Clopidogrel in Massive Cerebral Ischemia

For massive cerebral infarction, give aspirin 160-325 mg acutely (after excluding hemorrhage), but avoid dual antiplatelet therapy due to hemorrhagic transformation risk 3, 2.

Critical Management Points:

Acute Phase (First 48 Hours):

• Aspirin 160-325 mg is Class I, Level A recommendation 1, 2
• Do NOT use clopidogrel alone or in combination acutely—insufficient evidence and increased bleeding risk (Class III, Level C) 3
• Clopidogrel requires 5 days to reach maximal platelet inhibition at standard 75 mg dosing 3, 2
• Loading doses (300-600 mg) have been studied in small trials but lack robust evidence for massive strokes 2

Why Avoid Dual Therapy in Massive Strokes:

• Large infarct burden increases hemorrhagic transformation risk
• MATCH trial showed 1.3% absolute increase in life-threatening bleeding with aspirin + clopidogrel 5
• No proven benefit over monotherapy for completed strokes 5, 7

Exception—Minor Strokes Only: For NIHSS ≤3 or high-risk TIA (ABCD² ≥4), dual antiplatelet therapy (aspirin + clopidogrel) for 21-90 days reduces recurrent stroke, but this does NOT apply to massive infarctions 8, 7.

---

4. IVIG in Guillain-Barré Syndrome

Note: No specific evidence provided in the submitted materials for this topic. Based on general medical knowledge:

Administer IVIG 0.4 g/kg/day for 5 days (total 2 g/kg) as first-line treatment for GBS requiring intervention.

Key Points:

• Equally effective as plasma exchange
• Preferred in patients with autonomic instability or difficult vascular access
• Start when patient cannot walk independently (≥10 meters without assistance)
• No benefit from combining IVIG + plasma exchange
• Contraindications: IgA deficiency (anaphylaxis risk), renal impairment (osmotic nephropathy risk)

---

5. Deep Brain Stimulation in Parkinson's Disease

Note: No specific evidence provided in the submitted materials for this topic. Based on general medical knowledge:

Consider DBS for patients with motor fluctuations/dyskinesias inadequately controlled by medications after ≥4 years of levodopa therapy.

Candidate Selection Criteria:

• Good levodopa response (≥30% improvement in "off" state)
• Age typically <70 years (relative)
• No significant cognitive impairment (MoCA >24)
• No major psychiatric disease
• Realistic expectations

Target Selection:

• STN (subthalamic nucleus): Better motor symptom control, allows medication reduction
• GPi (globus pallidus interna): Better for dyskinesias, less cognitive risk

---

MODULE 3 – PAPER 2: NEPHROLOGY / HAEMATO-ONCOLOGY

6. Finerenone in Chronic Kidney Disease

Note: Limited evidence in submitted materials. Based on general knowledge:

Prescribe finerenone for patients with CKD (eGFR 25-90 mL/min/1.73m²) and type 2 diabetes with albuminuria despite maximal RAAS blockade.

Dosing:

• eGFR ≥60: Start 20 mg daily
• eGFR 25-59: Start 10 mg daily
• Titrate to 20 mg if tolerated and potassium <4.8 mEq/L

Key Benefits:

• Reduces CKD progression (composite of kidney failure, sustained eGFR decline, renal death)
• Reduces cardiovascular events (CV death, MI, stroke, HF hospitalization)
• Non-steroidal mineralocorticoid receptor antagonist—less hyperkalemia than spironolactone

---

7. Desidustat in CKD-Related Anemia

Note: No evidence provided in submitted materials. Based on general knowledge:

Desidustat is an oral HIF-prolyl hydroxylase inhibitor approved in India for CKD anemia; not yet FDA-approved in the US.

Mechanism:

• Stimulates endogenous erythropoietin production
• Improves iron utilization
• Alternative to ESAs (erythropoiesis-stimulating agents)

Typical Dosing:

• Start 25-50 mg three times weekly
• Titrate based on hemoglobin response
• Target Hb 10-12 g/dL (avoid >12 g/dL due to thrombotic risk)

---

8. IV Iron Supplementation in Iron Deficiency Anemia

Note: No specific evidence in submitted materials. Based on general knowledge:

Administer IV iron for iron deficiency anemia when oral iron fails, is not tolerated, or rapid repletion is needed (e.g., perioperative, severe anemia, ongoing losses).

Formulations & Dosing:

• Iron sucrose: 200 mg over 2-5 minutes, repeat doses to total deficit
• Ferric carboxymaltose: 750-1000 mg single dose (max 1000 mg/dose)
• Iron dextran: Requires test dose (anaphylaxis risk)

Advantages Over Oral:

• Bypasses GI absorption issues
• Faster repletion
• Better tolerated (no GI side effects)

Monitoring:

• Check ferritin and TSAT 4-6 weeks post-infusion
• Reticulocyte count peaks at 7-10 days

---

9. Immunotherapy in Lymphoma

Note: No specific evidence in submitted materials. Based on general knowledge:

Checkpoint inhibitors (anti-PD-1) are approved for relapsed/refractory classical Hodgkin lymphoma and primary mediastinal B-cell lymphoma after ≥2 prior therapies.

FDA-Approved Agents:

• Pembrolizumab: 200 mg IV every 3 weeks
• Nivolumab: 240 mg IV every 2 weeks or 480 mg every 4 weeks

CAR-T Cell Therapy:

Use CAR-T for relapsed/refractory large B-cell lymphoma after ≥2 lines of therapy:

• Axicabtagene ciloleucel (Yescarta)
• Tisagenlecleucel (Kymriah)
• Lisocabtagene maraleucel (Breyanzi)

Key Toxicities:

• Checkpoint inhibitors: Immune-related adverse events (pneumonitis, colitis, hepatitis, endocrinopathies)
• CAR-T: Cytokine release syndrome (manage with tocilizumab), neurotoxicity (ICANS)

---

10. Portable/Wearable Dialysis Devices for ESRD

Note: No specific evidence in submitted materials. Based on general knowledge:

Wearable artificial kidney (WAK) and portable dialysis devices remain investigational; not yet FDA-approved for routine clinical use.

Current Status:

• Phase II/III trials ongoing
• Potential advantages: Continuous therapy, improved quality of life, hemodynamic stability
• Challenges: Device size, battery life, infection risk, cost

Standard of Care Remains:

• In-center hemodialysis: 3x/week, 4 hours/session
• Home hemodialysis: More frequent, shorter sessions or nocturnal
• Peritoneal dialysis: Continuous ambulatory or automated

---

Key Exam Pearls by Topic

Stroke Management Algorithm:

1. 0-3 hours: IV alteplase (Class I)
2. 3-4.5 hours: Consider IV alteplase (Grade 2C)
3. After thrombolysis or if ineligible: Start aspirin 160-325 mg at 24 hours
4. Never combine aspirin + thrombolysis within 24 hours
5. Massive strokes: Aspirin monotherapy only—avoid dual antiplatelets

CKD & Stroke Connection:

CKD (especially ESRD) independently increases stroke risk and worsens outcomes 9, 10, 11:

• 2-fold increased mortality with ESRD 9
• More cerebral small vessel disease burden 11
• Thrombolysis is NOT contraindicated in CKD—outcomes similar to non-CKD patients 9

Antiplatelet Hierarchy for Secondary Prevention:

1. First-line: Aspirin 75-100 mg, clopidogrel 75 mg, or aspirin/dipyridamole
2. Aspirin allergy: Clopidogrel
3. Minor stroke/high-risk TIA only: Dual therapy (aspirin + clopidogrel) for 21-90 days, then monotherapy
4. Never routinely combine aspirin + clopidogrel long-term—increased bleeding without stroke benefit 5, 1, 7